A Randomized, Double-Blind, Placebo Controlled, Multi-Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs LIV 001 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Liveome
- 31 Dec 2024 New trial record